Mercury Bio

Mercury Bio is developing the next generation of biomolecular drug delivery platforms. RNA and small molecule drugs can be delivered to highly specific cells via our platform without triggering an immune response. Our platform will enable drug developers to accelerate their products to market by reducing the barriers and risks encountered with traditional drug delivery systems. Most importantly, low cost, rapid market entry, and high specificity will greatly improve patient outcomes.